Browse our 650+ Publications​

Latest Publications

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Reddy SM., el at.
November 2020
Authors and Affiliates
Sangeetha M Reddy 1,2, Alexandre Reuben 3,4, Souptik Barua 5,6, Hong Jiang 3, Shaojun Zhang 7, Linghua Wang 7, Vancheswaran Gopalakrishnan 3, Courtney W Hudgens 8, Michael T Tetzlaff 8,9, James M Reuben 10,11, Takahiro Tsujikawa 12,13, Lisa M Coussens 12, Khalida Wani 8, Yan He 8, Lily Villareal 11, Anita Wood 11, Arvind Rao 6,14, Wendy A Woodward 11,15, Naoto T Ueno 16,11, Savitri Krishnamurthy 17,18, Jennifer A Wargo 19,7, Elizabeth A Mittendorf 20,21,22; 1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2 Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. 3 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5 Department of Electrical and Computer Engineering, Rice University, Houston, Texas. 6 Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan. 7 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 10 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 11 Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. 12 Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon. 13 Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. 14 Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 15 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 16 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 17 Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 18 Department of Breast Surgical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 19 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 20 Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 21 Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 22 Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Keymeulen B., et al.
November 2020
Authors and Affiliates
Bart Keymeulen 1,2, André van Maurik 3, Dave Inman 3, João Oliveira 4, Rene McLaughlin 5, Rachel M Gittelman 6, Bart O Roep 7,8, Pieter Gillard 9, Robert Hilbrands 10,11, Frans Gorus 10,11, Chantal Mathieu 9, Ursule Van de Velde 10,11, Nicolas Wisniacki 3, Antonella Napolitano 12; 1 Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium. bart.keymeulen@vub.be. 2 Belgian Diabetes Registry, Brussels, Belgium. bart.keymeulen@vub.be. 3 GlaxoSmithKline Medicines Research Centre, Stevenage, UK. 4 GlaxoSmithKline, Global Clinical Operations, Cambridge, UK. 5 Department of Immunology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. 6 Adaptive Biotechnologies, Seattle, WA, USA. 7 Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. 8 Department of Diabetes Immunology, Diabetes & Metabolism Research Institute, Beckman Research Institute at the City of Hope, Duarte, CA, USA. 9 Department of Endocrinology, University Hospitals Leuven-KUL, Leuven, Belgium. 10 Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium. 11 Belgian Diabetes Registry, Brussels, Belgium. 12 GlaxoSmithKline Medicines Research Centre, Stevenage, UK. Antonella.2.napolitano@gsk.com.

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Reinke S., et al.
November 2020
Authors and Affiliates
Sarah Reinke 1, Paul J Bröckelmann 2, Ingram Iaccarino 1, Maria Alejandra Garcia-Marquez 2, Sven Borchmann 3, Franziska Jochims 4, Michaela Kotrova 5, Karol Pal 6, Monika Brüggemann 5, Elena Hartmann 7, Stephanie Sasse 8, Carsten Kobe 9, Stephan Mathas 10, Martin Soekler 11, Ulrich Keller 12, Matthias Bormann 13, Andreas Zimmermann 14, Julia Richter 15, Michael Fuchs 3, Bastian von Tresckow 16, Peter Borchmann 17, Hans Schlößer 18, Michael von Bergwelt-Baildon 19, Andreas Rosenwald 20, Andreas Engert 21, Wolfram Klapper 22; 1 University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. 2 University Hospital of Cologne, Cologne, Germany. 3 University of Cologne, Cologne, Germany. 4 University Hospital Schleswig-Holstein, Campus Kiel, Groß Grönau, Germany. 5 Universitätsklinikum Schleswig-Holstein, Kiel, Germany. 6 University Hospital Schleswig-Holstein, Kiel, Germany. 7 University of Würzburg, Würzburg, Germany. 8 Cologne, Germany. 9 Department of Nuclear Medicine, University of Cologne, Cologne, Germany, Cologne, Germany. 10 Max-Delbrück-Center for Molecular Medicine, Berlin, Germany. 11 Hospital Thun, Thun, Switzerland. 12 Charite - Universitätsmedizin Berlin, Berlin, Germany. 13 Klinikum Bremen-Mitte, Bremen, Germany. 14 University Hospital LMU Munich, Munich, Germany. 15 Christian-Albrechts University Kiel, Kiel, Germany. 16 University Hospital Essen, Germany. 17 Uniklinik Koeln, Koeln, Germany. 18 University Hospital of Cologne. 19 University Hospital LMU, Munich, Germany. 20 University of Wuerzburg, Wuerzburg, Germany. 21 University Hospital of Cologne, Koeln, Germany. 22 Department of Pathology, Kiel, Kiel, Germany.

Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis

Durgin JS., et al.
November 2020
Authors and Affiliates
Joseph S Durgin 1, Neha N Jariwala 1, Maria Wysocka 1, Kevin K Zhang 1, Amit Maity 2, Bernice Benoit 1, John P Plastaras 2, Daniel J Lewis 1, Jaclyn M Rosenthal 1, Jessica E Teague 3, Sara Berg 1, Christina Del Guzzo 1, Ellen J Kim 1, Carmela Vittorio 1, Paul L Haun 1, Sara S Samimi 1, Jennifer Villasenor-Park 1, Joanne Inverso 1, Rachael A Clark 3, Alain H Rook 1; 1 Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 2 Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 3 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Unbiased Profiling Reveals Compartmentalization of Unconventional T-Cells Within the Intestinal Mucosa Irrespective of HIV Infection

Magnoumba M., et al.
November 2020
Authors and Affiliates
Magalli Magnoumba 1, Alveera Singh 1, Paul Ogongo 1,2, Julia Roider 3,4, Osaretin Asowata 1, Michael Fehlings 5, Farina Karim 1, Thumbi Ndung'u 1,6,7, Frank Anderson 8, Alasdair Leslie 1,7, Henrik Kløverpris 1,7,9; 1 Africa Health Research Institute (AHRI), University of KwaZulu-Natal (UKZN), Durban, South Africa. 2 Institute of Primate Research, National Museums of Kenya, Nairobi, Kenya. 3 Department of Infectious Diseases, Medizinische Klinik IV, Ludwig-Maximilians-University Munich, Munich, Germany. 4 German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany. 5 ImmunoScape Pte Ltd, Singapore, Singapore. 6 HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. 7 Division of Infection and Immunity, University College London (UCL), London, United Kingdom. 8 Department of Surgery, Inkosi Albert Luthuli Hospital, Durban, South Africa. 9 Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Dimopoulos MA., et al.
November 2020
Authors and Affiliates
Meletios A Dimopoulos 1, Sara Bringhen 2, Pekka M Anttila 3, Marcelo Capra 4, Michele Cavo 5, Craig Emmitt Cole 6, Cristina Gasparetto 7, Vania Tietsche de Moraes Hungria 8, Matthew W Jenner 9, Vladimir I Vorobyev 10, Eduardo Patricio Yanez Ruiz 11, Jian Y Yin 12, Rao Saleem 12, Maeva Hellet 13, Sandrine Macé 14, Bruno Paiva 15, Ravi Vij 16; 1 National and Kapodistrian University of Athens, Athens, Greece. 2 University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. 3 Helsinki University and Helsinki University Hospital, Helksinki, Finland. 4 Hospital Mãe de Deus, Porto Alegre, Brazil. 5 Seràgnoli Institute of Hematology, Bologna, Italy. 6 Michigan State University, East Lansing, Michigan, United States. 7 Duke University. 8 Clinica Sao Germano, São Paulo, Brazil. 9 University Hospital Southampton, Southampton, United Kingdom. 10 S.P. Botkin Hospital, Moscow, Russian Federation. 11 Universidad de la Frontera, Temuco, Chile. 12 Sanofi, Bridgewater, New Jersey, United States. 13 Ividata (for Sanofi), Paris, France. 14 Sanofi, Paris, France. 15 Clinica Universidad de Navarra, Pamplona, Spain. 16 Washington University, St Louis, Missouri, United States.

CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

Corgnac S, et al.
October 2020
Authors and Affiliates
Stephanie Corgnac,1 Ines Malenica,1 Laura Mezquita,2,9,10 Edouard Auclin,3,9 Elodie Voilin,1 Jamila Kacher,1 Heloise Halse,1 Laetitia Grynszpan,1 Nicolas Signolle,4 Thibault Dayris,5 Marine Leclerc,1 Nathalie Droin,5 Vincent de Montpreville,1,6 Olaf Mercier,6 Pierre Validire,7 Jean-Yves Scoazec,5 Christophe Massard,8 Salem Chouaib,1 David Planchard,2 Julien Adam,1,9 Benjamin Besse,2,9 and Fathia Mami-Chouaib1,11,*; 1 INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Faculte de Medecine, Universite Paris-Sud, Universite Paris-Saclay, 94805 Villejuif, France 2 Department of Cancer Medicine, Gustave Roussy, Institut d’Oncologie Thoracique, Gustave Roussy, Universite Paris-Saclay, 94805 Villejuif, France 3 Gastrointestinal and Medical Oncology Department, Hopital Europe en Georges Pompidou, Paris, France 4 INSERM Unit U981, Department of Experimental Pathology, Gustave Roussy, Universite Paris-Sud, Universite Paris-Saclay, 94805 Villejuif, France 5 Department of Biology and Medical Pathology, Gustave Roussy, 94805 Villejuif, France 6 Hopital Marie-Lannelongue, Service d’Anatomie Pathologique, 92350 Le-Plessis-Robinson, France 7 Institut Mutualiste Montsouris, Service d’Anatomie Pathologique, 75014 Paris, France 8 Drug Development Department, Gustave Roussy, Universite Paris-Saclay, 94805 Villejuif, France 9 These authors contributed equally 10 Present address: Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), and Medical Oncology Department, Hospital Clinic, Barcelona, Spain 11 Lead Contact * Correspondence: fathia.mami-chouaib@gustaveroussy.fr

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Oba T., et al.
October 2020
Authors and Affiliates
Takaaki Oba 1,8, Mark D. Long 2,8, Tibor Keler3, Henry C. Marsh 3, Hans Minderman 4, Scott I. Abrams 5,9, Song Liu2,9 & Fumito Ito 1,5,6,7; 1 Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2 Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 3 Celldex Therapeutics, Inc., Hampton, NJ, USA. 4 Flow & Image Cytometry Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 5 Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 6 Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 7 Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA. 8 These authors contributed equally: Takaaki Oba, Mark D. Long. 9 These authors jointly supervised: Scott I. Abrams, Song Liu. email: fumito.ito@roswellpark.org

The Immune Phenotype of Isolated Lymphoid Structures in Non-Tumorous Colon Mucosa Encrypts the Information on Pathobiology of Metastatic Colorectal Cancer

Mungenast F, et al.
October 2020
Authors and Affiliates
Felicitas Mungenast 1,†, Anastasia Meshcheryakova 1,†,*, Andrea Beer 2, Martina Salzmann 1, Dietmar Tamandl 3, Thomas Gruenberger 4,‡, Peter Pietschmann 1, Oskar Koperek 2,§, Peter Birner 2, Ilan Kirsch 5, Harlan Robins 5, Martina Mittlboeck 6, Markus Jaritz 7, Michael Bergmann 8, Philip Zimmermann 9 and Diana Mechtcheriakova 1,*; 1 Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna 1090, Austria; felicitas.mungenast@meduniwien.ac.at (F.M.); martina.salzmann@meduniwien.ac.at (M.S.); peter.pietschmann@meduniwien.ac.at (P.P.) 2 Department of Pathology, Medical University of Vienna, Vienna 1090, Austria; andrea.beer@meduniwien.ac.at (A.B.); Koperek@labor-kaserer.at (O.K.); peter.birner@meduniwien.ac.at (P.B.) 3 Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna 1090, Austria; dietmar.tamandl@meduniwien.ac.at 4 Department of Surgery, Kaiser Franz Josef Hospital, Vienna 1100, Austria; thomas.gruenberger@gesundheitsverbund.at 5 Adaptive Biotechnologies Corporation, Seattle, WA 98102, USA; lkirsch@adaptivebiotech.com (I.K.); hrobins@adaptivebiotech.com (H.R.) 6 Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna 1090, Austria; martina.mittlboeck@meduniwien.ac.at 7 Research Institute of Molecular Pathology, Vienna Biocenter, Vienna 1030, Austria; Markus.Jaritz@imp.ac.at 8 Department of Surgery, Medical University of Vienna, Vienna 1090, Austria; michael.bergmann@meduniwien.ac.at 9 Nebion AG, Zürich, 8048, Switzerland; phz@nebion.com * Correspondence: diana.mechtcheriakova@meduniwien.ac.at (D.M.); anastasia.meshcheryakova@meduniwien.ac.at (A.M.) † These authors contributed equally to this work. ‡ Current affiliation: Department of Surgery I, Rudolf Foundation Clinic, Vienna 1030, Austria. § Current affiliation: Clinical Pathology Laboratory Kaserer, Koperek and Beer, Vienna 1030, Austria.

Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T

Zhang L., et al.
Cancer Immunology Research
October 2020
Authors and Affiliates
Li Zhang 1,2, Harini Kandadi 3, Hai Yang 2, Jason Cham 1 4, Tao He 5, David Y Oh 1, Nadeem A Sheikh 3, Lawrence Fong 6; 1 Department of Medicine, University of California San Francisco, San Francisco, California. 2 Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California. 3 Dendreon Pharmaceuticals LLC, Seattle, Washington. 4 Department of Internal Medicine, Scripps Green Hospital, La Jolla, California. 5 Department of Mathematics, San Francisco State University, San Francisco, California. 6 Department of Medicine, University of California San Francisco, San Francisco, California. lawrence.fong@ucsf.edu.